AbbVie Inc.
10/03/2025 | Press release | Distributed by Public on 10/03/2025 14:09
Business/Financial Results (Form 8-K)
AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
| (in millions, except per share data) | Quarter Ended September 30, 2025 | Full-Year Ended December 31, 2025 | |||||||||||||||||||||||||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||||||||||||||||||
|
Previously announced guidance excluding Q3 2025 acquired IPR&D and milestones expense
|
$ | - | $ | 3.24 | $ | 3.28 | $ | 1,071 | $ | 11.88 | $ | 12.08 | |||||||||||||||||||||||
| Q3 2025 acquired IPR&D and milestones expense | 2,680 | (1.50) | (1.50) | 2,680 | (1.50) | (1.50) | |||||||||||||||||||||||||||||
|
Guidance including Q3 2025 acquired IPR&D and milestones expensea
|
$ | 2,680 | $ | 1.74 | $ | 1.78 | $ | 3,751 | $ | 10.38 | $ | 10.58 | |||||||||||||||||||||||
a The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2025, as both cannot be reliably forecasted.
1
AbbVie Inc. published this content on October 03, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on October 03, 2025 at 20:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]